SBC Medical Group Holdings Inc. (NASDAQ: SBC) is making a strategic push into the U.S. cosmetic aesthetics market through its recent investment in OrangeTwist, a U.S.-based medspa chain. This partnership, announced late last month, positions SBC to leverage its operational expertise and financial resources to expand OrangeTwist's 24 locations across six states, targeting underserved markets with high demand for non-invasive treatments.
The medical aesthetics industry is projected to grow from $34 billion to $48 billion by 2030, driven by demand for injectables, fillers, and laser treatments. SBC's global head of planning and strategy, Stephen Rodgers, told Benzinga that the company seeks local partnerships rather than replicating its Japanese model. The collaboration with OrangeTwist includes joint operations, product development, and leveraging SBC's management system to optimize procurement and clinical workflows.
Beyond aesthetics, SBC is positioning itself in the longevity industry, which Gabelli Research estimates will grow from $85 billion in 2025 to over $120 billion by 2030. With an aging population—4.1 million Americans turning 65 annually through 2027—demand for healthspan-enhancing services like AI diagnostics and regenerative therapies is rising. SBC aims to offer these through its existing infrastructure.
SBC's expansion is not limited to the U.S. The company is also growing in Japan and Southeast Asia, applying its proven business model to help partner clinics with training, procurement, and management. By standardizing services across regions, SBC ensures consistent quality and pricing. The company's strategy rests on partnering with scalable regional operators, deploying expertise for efficiency, and securing first-mover advantages in emerging markets.
In the U.S., SBC and OrangeTwist plan to address "white space"—cities with high demand but few competitors—by opening new locations quickly. This first-mover advantage could help them capture market share before rivals enter. The partnership also involves developing branded products and cross-selling existing ones.
Investors and industry watchers are closely watching SBC's moves, as the company transitions from a local Japanese operator to a global network. With a track record of managing over six million patient visits annually across 258 clinics, SBC's partnership model could be replicated in other countries, creating a unified brand in aesthetic medicine. For more information, click here.
